Clive Stanway

Clive is an independent cancer drug discovery and development advisor. In addition to the Babraham Research Campus, Clive holds non-executive director positions at Atelerix Ltd and CytoSeek Ltd and serves on the scientific advisory boards of 4Bio Capital and ANGLE plc.

Clive trained as a scientist in cell and molecular biology at Imperial College and Oxford University, rising to junior faculty status. He transitioned into cancer drug discovery and development firstly at Xenova and Prolifix and subsequently at Cancer Research UK where he established and led a team operating to pharmaceutical company standards. During the course of his career Clive has been involved in projects which have matured from discovery status into clinical development.  For many years, he was part of the executive team in the commercial arm of Cancer Research UK, during which time it grew to have an interest in four drugs on the market and multimillion pound revenues. It was also the intellectual property contributor to many cancer therapeutic and diagnostic start-up companies.Clive was a significant driver in both the initiation and the completion of various deals in the pharmaceutical sector, including companies such as Celgene and FORMA Therapeutics.